Comparative Pharmacology
Head-to-head clinical analysis: DIHYDROERGOTAMINE MESYLATE versus WIGRETTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIHYDROERGOTAMINE MESYLATE versus WIGRETTES.
DIHYDROERGOTAMINE MESYLATE vs WIGRETTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dihydroergotamine mesylate is an ergot alkaloid with potent agonist activity at serotonin 5-HT1B/1D receptors, leading to vasoconstriction of cranial blood vessels. It also has partial agonist/antagonist activity at alpha-adrenergic and dopamine receptors, contributing to its antimigraine effects.
Nicotine replacement therapy: binds to nicotinic acetylcholine receptors in the brain, releasing dopamine and providing nicotine to reduce withdrawal symptoms and cravings.
1 mg intramuscularly or subcutaneously, repeat at 1-hour intervals as needed, maximum 3 mg per 24 hours and 6 mg per week; intravenous use is reserved for severe cases: 0.5-1 mg IV, may repeat once after 1 hour, maximum 2 mg per 24 hours.
1 mg sublingually as needed for smoking cessation, up to 4 times daily. Maximum daily dose: 4 mg.
None Documented
None Documented
Terminal half-life is approximately 9 hours (range 7-13 hours) after IM administration; clinical effect duration corresponds to this elimination phase.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-30 hours in moderate renal impairment.
Primarily hepatic metabolism; <10% excreted unchanged in urine; biliary/fecal excretion accounts for ~90% of metabolites.
Renal excretion of unchanged drug accounts for 50-60% of the dose; biliary/fecal elimination accounts for 20-30%; remainder metabolized.
Category D/X
Category C
Ergot Alkaloid
Ergot Alkaloid